news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

With 100 days left before the 7th China International Import Expo, Abbott announced that it will participate in the Expo again, fully displaying cutting-edge technologies and diversified innovative achievements in fields such as diagnosis, medical devices, nutritional products and pharmaceuticals, to meet the growing health management needs of medical institutions, medical staff and the general public, and continue to promote the high-quality development of China's medical and health industry.

It is reported that this time Abbott will appear in the medical equipment and pharmaceutical health exhibition area with the theme of "Technology Galaxy, Unlimited Health" to create a creative and healthy space, and will continue to bring a series of new products to allow visitors to fully appreciate the power of life given by Abbott's cutting-edge "star" technology and embrace unlimited health possibilities.

The reporter learned that Abbott has displayed hundreds of innovative life science technologies in the five consecutive years of participating in the CIIE. As a global leader in the diagnosis and treatment of cardiovascular diseases, Abbott has a full range of solutions and products for the treatment of coronary and peripheral artery diseases, abnormal heart rhythms, atrial fibrillation, structural heart disease and heart failure. At previous CIIEs, Abbott has launched new products every year, bringing breakthrough cutting-edge technologies covering diagnosis, treatment, and management, demonstrating the world's leading innovation capabilities, allowing patients and doctors to better manage heart and vascular health. Among them, the AVEIRTM VR single-chamber implantable leadless pacemaker, which debuted at the fifth CIIE, has now been officially approved for marketing in China, and the first batch of surgeries have been completed recently, bringing new treatment options to patients with bradycardia; since its debut at the CIIE, the breakthrough device product MitraClipTM transcatheter mitral valve clip and steerable guide catheter for minimally invasive treatment of mitral regurgitation have also been successfully launched in China, filling the domestic treatment gap with minimally invasive technology, helping many patients and families improve their quality of life and regain a better life.

Abbott focuses on the integration of health and digital technology. In terms of leading continuous glucose monitoring and management, the world's leading bio-wearable technology instant glucose monitoring system is also a breakthrough technology product that has attracted much attention at previous exhibitions. Today, Abbott Instant has served more than 500,000 Chinese users. In addition, a number of digital products in the Instant family, including Instant Treasure, Instant Pass, and Instant Butler WeChat applet, have also been released one after another, bringing users a more convenient and personalized one-stop sugar control experience.

As a global leader in diagnostics, nutrition and pharmaceuticals, Abbott has unveiled at the CIIE the new generation of Alinity diagnostic system family that helps laboratories improve quality and efficiency, the GLP laboratory automation system that helps medical diagnosis, the new generation of Abbott Total to provide comprehensive nutritional support for the elderly and rehabilitation population, and the high-quality drug Fenyuening to protect the health of menopausal women. Abbott's goal is to provide products and services to 3 billion people worldwide each year by 2030. Thanks to the powerful spillover effect of the CIIE, a number of cutting-edge technologies and products have been approved and landed in the Chinese market, turning from exhibits into medical and health products that are well used by the Chinese public.

Author: Xu Jinghui

Text: Xu Jinghui Editor: Zhang Tianchi Editor-in-chief: Rong Bing

Please indicate the source when reprinting this article.